Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 17 04:00PM ET
210.59
Dollar change
-2.54
Percentage change
-1.19
%
IndexS&P 500 P/E42.52 EPS (ttm)4.95 Insider Own0.39% Shs Outstand84.29M Perf Week1.41%
Market Cap17.75B Forward P/E13.19 EPS next Y15.97 Insider Trans-15.61% Shs Float83.97M Perf Month5.59%
Income433.10M PEG4.96 EPS next Q3.81 Inst Own95.69% Short Float2.47% Perf Quarter-2.79%
Sales12.30B P/S1.44 EPS this Y9.44% Inst Trans-2.80% Short Ratio2.62 Perf Half Y0.32%
Book/sh94.42 P/B2.23 EPS next Y7.61% ROA2.17% Short Interest2.07M Perf Year12.92%
Cash/sh1.18 P/C178.76 EPS next 5Y8.58% ROE4.36% 52W Range179.58 - 234.09 Perf YTD-7.35%
Dividend Est.2.52 (1.20%) P/FCF25.98 EPS past 5Y-11.14% ROI3.70% 52W High-10.04% Beta1.07
Dividend TTM2.88 (1.37%) Quick Ratio0.76 Sales past 5Y2.87% Gross Margin25.90% 52W Low17.27% ATR (14)3.82
Dividend Ex-DateMay 24, 2024 Current Ratio0.88 EPS Y/Y TTM-54.91% Oper. Margin9.05% RSI (14)57.66 Volatility1.73% 1.98%
Employees67000 Debt/Eq0.75 Sales Y/Y TTM-16.64% Profit Margin3.52% Recom1.70 Target Price241.47
Option/ShortYes / Yes LT Debt/Eq0.47 EPS Q/Q12.53% Payout60.36% Rel Volume0.92 Prev Close213.13
Sales Surprise1.88% EPS Surprise5.61% Sales Q/Q-15.92% EarningsApr 25 BMO Avg Volume790.85K Price210.59
SMA202.94% SMA501.04% SMA200-0.82% Trades Volume730,665 Change-1.19%
Date Action Analyst Rating Change Price Target Change
Mar-25-24Upgrade Argus Hold → Buy $250
Feb-26-24Initiated Leerink Partners Outperform $260
Feb-09-24Initiated Evercore ISI In-line $240
Jan-03-24Initiated Barclays Equal Weight $222
Sep-06-23Initiated HSBC Securities Hold $210
Dec-12-22Downgrade Citigroup Buy → Neutral $275 → $250
Sep-19-22Downgrade Argus Buy → Hold
Aug-22-22Resumed Morgan Stanley Overweight $300
Jan-28-22Downgrade Deutsche Bank Buy → Hold $330 → $294
Jan-11-21Upgrade Argus Hold → Buy $245
May-16-24 11:00AM
09:49AM
06:22AM
05:42AM
May-15-24 08:00AM
10:41AM Loading…
May-09-24 10:41AM
May-08-24 06:59AM
06:56AM
03:44AM
May-07-24 04:05PM
May-02-24 02:22AM
May-01-24 01:03AM
Apr-30-24 01:58PM
08:41AM
Apr-29-24 10:17AM
07:00AM Loading…
07:00AM
Apr-26-24 11:14AM
10:34AM
07:55AM
01:06AM
Apr-25-24 01:41PM
01:11PM
12:45PM
10:18AM
09:30AM
09:22AM
08:35AM
07:09AM
07:06AM
06:58AM
10:25PM Loading…
Apr-24-24 10:25PM
10:23PM
09:27PM
09:19PM
Apr-22-24 09:16AM
Apr-19-24 05:34AM
Apr-18-24 12:10PM
10:01AM
Apr-16-24 08:42AM
Apr-15-24 07:00AM
Apr-12-24 09:10AM
Apr-11-24 06:59AM
Apr-10-24 06:49AM
Apr-09-24 09:03AM
Apr-08-24 09:34AM
07:09AM
07:03AM
07:00AM
Apr-05-24 07:00AM
Apr-03-24 11:01AM
11:00AM
Apr-02-24 11:20AM
07:00AM
Apr-01-24 12:42PM
08:00AM
Mar-30-24 01:30AM
Mar-29-24 09:00AM
Mar-28-24 11:08PM
08:00AM
Mar-27-24 07:00AM
Mar-25-24 07:03AM
Mar-20-24 07:00AM
Mar-18-24 09:44AM
Mar-16-24 10:29AM
Mar-15-24 09:25AM
Mar-11-24 11:00AM
Mar-08-24 10:26AM
Mar-07-24 07:00AM
Mar-05-24 07:00AM
Feb-27-24 12:08AM
Feb-26-24 08:45AM
05:01AM
Feb-21-24 12:00PM
08:19AM
Feb-19-24 06:28AM
Feb-16-24 09:41AM
07:15AM
12:59AM
Feb-15-24 03:29PM
12:48PM
09:30AM
08:10AM
07:37AM
07:35AM
07:30AM
06:56AM
Feb-12-24 09:16AM
Feb-08-24 10:00AM
04:08AM
Feb-07-24 09:05AM
Feb-05-24 08:16AM
Feb-01-24 04:55PM
07:00AM
Jan-31-24 07:00AM
Jan-16-24 06:58AM
Jan-12-24 06:57AM
Jan-11-24 11:21AM
Jan-10-24 08:02AM
Jan-05-24 04:45AM
Jan-02-24 07:00AM
Laboratory Corp. of America Holdings operates as a life sciences company, which engages in the provision of vital information to help health professionals make clear and confident decisions. It operates through the Drug Development and Diagnostics segments. The Drug Development segment consists of lead optimization, preclinical safety assessment, analytical services, clinical trials, central laboratories, biomarkers, and companion diagnostics, market access, and technology solutions. The Diagnostics segment includes primary care, women's health, specialty medicine, oncology, ACOs, and hospitals and health systems. The company was founded in 1971 and is headquartered in Burlington, NC.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
van der Vaart Sandra DEVP, Chief Legal OfficerMay 14 '24Sale210.832,000421,6555,637May 16 08:02 AM
ANDERSON KERRII BDirectorMay 02 '24Sale200.1025050,02515,722May 02 04:29 PM
ANDERSON KERRII BDirectorApr 30 '24Sale204.1325051,03415,972May 02 04:29 PM
Wilkinson Peter JSVP, Chief Accounting OfficerApr 29 '24Sale204.332,439498,3582,087May 01 06:29 PM
Schroeder Mark SEVP, Pres Diagnostics & COOApr 01 '24Sale217.296,4771,407,3875,036Apr 03 08:35 AM
Summy Amy B.EVP, Chief Marketing OfficerApr 01 '24Sale217.293,500760,5153,975Apr 03 08:34 AM
van der Vaart Sandra DEVP, Chief Legal OfficerMar 28 '24Sale216.743,553770,0777,637Mar 29 05:54 PM
Schroeder Mark SEVP, Pres Diagnostics & COOMar 07 '24Option Exercise117.092,119248,11410,084Mar 11 08:59 AM
Schroeder Mark SEVP, Pres Diagnostics & COOMar 07 '24Sale218.455,0481,102,7365,036Mar 11 08:59 AM
Summy Amy B.EVP, Chief Marketing OfficerMar 07 '24Sale218.4522749,5883,859Mar 11 08:56 AM
EISENBERG GLENN AChief Financial Officer, EVPFeb 21 '24Option Exercise163.6314,0542,299,65658,099Feb 22 03:05 PM
EISENBERG GLENN AChief Financial Officer, EVPFeb 21 '24Sale215.9734,5047,451,86623,595Feb 22 03:05 PM
DiVincenzo Jonathan P.EVP, Pres, Central Labs & IntlFeb 21 '24Sale215.49500107,7453,401Feb 22 03:04 PM
van der Vaart Sandra DEVP, Chief Legal OfficerFeb 13 '24Sale226.4523753,6697,637Feb 15 08:32 AM
van der Vaart Sandra DEVP, Chief Legal OfficerFeb 08 '24Sale222.0625957,5147,637Feb 09 12:19 PM
van der Vaart Sandra DEVP, Chief Legal OfficerFeb 05 '24Sale220.5719342,5707,637Feb 06 03:47 PM
Wilkinson Peter JSVP, Chief Accounting OfficerNov 16 '23Sale210.711,384291,6272,087Nov 20 12:23 PM
ANDERSON KERRII BDirectorAug 08 '23Sale211.575,0001,057,83215,275Aug 10 08:55 AM
van der Vaart Sandra DEVP, Chief Legal OfficerJun 29 '23Sale240.0021250,8807,605Jul 03 11:52 AM
Kirchgraber Paul RCEO, Covance Drug DevelopmentMay 19 '23Option Exercise182.514,300784,79317,246May 23 08:06 AM
Kirchgraber Paul RCEO, Covance Drug DevelopmentMay 19 '23Sale216.914,300932,70712,946May 23 08:06 AM